Match tier Listed
Presence Current · Arkansas
Last published 2022
Sources OpenAlex · ORCID
Refreshed 2026-08-08

Monica Graziutti

Researcher

UAMS

Also affiliated: Winthrop Rockefeller Foundation (2021–2022)

Unknown Researcher

4 h-index 4 pubs 47 cited

Research Areas

Biomedical Subjects

  • Receptors, Chimeric Antigen
  • Multiple Myeloma
  • Hematopoietic Stem Cell Transplantation
  • Bone Marrow
  • Humans
  • Transplantation, Autologous
  • Bone Marrow Transplantation
  • Neoplasm, Residual
  • Stem Cell Transplantation

OverviewAI-generated summary

Monica Graziutti's research focuses on multiple myeloma, particularly in the context of hematopoietic stem cell transplantation. She has investigated salvage autologous stem cell transplantation for patients with daratumumab-refractory multiple myeloma and examined the feasibility of outpatient stem cell transplantation, identifying risk factors for hospital admission. Her work also includes exploring tandem autologous stem cell transplantation for patients with persistent minimal residual disease in the bone marrow after an initial transplantation. Graziutti has collaborated with Sharmilan Thanendrarajan, Maurizio Zangari, Sravani Gundarlapalli, and Guido Tricot on multiple publications within the University of Arkansas for Medical Sciences. Her scholarship metrics include an h-index of 4, with a total of 4 publications and 47 citations.

Metrics

  • h-index: 4
  • Publications: 4
  • Citations: 47

Selected Publications

  • Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)
    Journal of Clinical Medicine 13 citations DOI OpenAlex
  • Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022)
    American Journal of Hematology 6 citations DOI OpenAlex
  • Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma (2021)
    Cancers 14 citations DOI OpenAlex
  • Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5 (2008)
    Blood 14 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

34 Collaborators 5 Institutions 1 Country

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics

Naveen Yarlagadda University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation Cancer Treatment and Pharmacology
Good match 4 shared topics
Sruthi Vellanki University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation Cancer Treatment and Pharmacology
Good match 4 shared topics
Manojna Konda University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation Cancer Treatment and Pharmacology
Good match 4 shared topics
Kerri Hill University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation Cancer Treatment and Pharmacology
Good match 3 shared topics
Anusha Jillella University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation Cancer Treatment and Pharmacology
Good match 4 shared topics
Munawwar Hussain University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation Cancer Treatment and Pharmacology
Good match 4 shared topics